Skip to main content
Premium Trial:

Request an Annual Quote

Wylie Chenn, Greg Lucier, Qiagen

Premium

Migrations

Serologicals has named Wylie Chenn as regional director for the Asia/Pacific region, the company said last week.

Chenn was most recently general manager, bioscience division for the Asia/Pacific region for Fisher Scientific. He received a BS in marketing and international business from Brigham Young University and an MBA from the University of Washington.


Invitrogen President and CEO Greg Lucier has become a member of the board of trustees of the Burnham Institute, the La Jolla, Calif.-based institute said last week.

 

Products

Qiagen last week announced the launch of its Human Druggable Genome siRNA Set V2.0. It made the first delivery of the product to the Scripps Research Institute in Florida.

The new Druggable Genome Set enables gene silencing studies of 6,692 potential human druggable targets, Qiagen said. The siRNAs are designed using Qiagen's HiPerformance siRNA Design Algorithm, which ensures maximum silencing and minimum risk of non-specific events, Qiagen said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.